<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35134679</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1768-3254</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>231</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of medicinal chemistry</Title>
          <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.</ArticleTitle>
        <Pagination>
          <StartPage>114161</StartPage>
          <MedlinePgn>114161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2022.114161</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(22)00063-0</ELocationID>
        <Abstract>
          <AbstractText>Voriconazole (VCZ) was the first approved triazole antifungal drug with 1-(1H-1,2,4-triazol-1-yl)butan-2-ol substructure. This drug showed a broad spectrum of activity, especially against yeasts and molds, and opened a new avenue toward the novel class of systemic antifungal agents. Modification of 2-fluoropyrimidine in the side chain of VCZ resulted in a newer generation of triazolylbutanols including efinaconazole, albaconazole, ravuconazole, and isavuconazole with the favorable antifungal spectrum, enhanced pharmacokinetic properties, and tolerable toxicity profiles. Due to the importance of triazolylbutanols in the discovery and development of new antifungal agents, in this review we have focused on the synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole. This comprehensive review provides highlighting scope for medicinal chemists for the design, synthesis and development of novel potential antifungal drugs having better activity, pharmacokinetic property and toxicity profile.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ghobadi</LastName>
            <ForeName>Elham</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saednia</LastName>
            <ForeName>Shahnaz</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Farabi Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emami</LastName>
            <ForeName>Saeed</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: semami@mazums.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Eur J Med Chem</MedlineTA>
        <NlmUniqueID>0420510</NlmUniqueID>
        <ISSNLinking>0223-5234</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JFU09I87TR</RegistryNumber>
          <NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="Y">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005658" MajorTopicYN="Y">Fungi</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antifungal activity</Keyword>
        <Keyword MajorTopicYN="N">SAR study</Keyword>
        <Keyword MajorTopicYN="N">Synthesis</Keyword>
        <Keyword MajorTopicYN="N">Triazoles</Keyword>
        <Keyword MajorTopicYN="N">Voriconazole</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>20</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35134679</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejmech.2022.114161</ArticleId>
        <ArticleId IdType="pii">S0223-5234(22)00063-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
